🇺🇸 FDA
Patent

US 9657090

Method of treating alveolar bone loss through the use of anti-sclerostin antibodies

granted A61KA61K2039/505A61K39/3955

Quick answer

US patent 9657090 (Method of treating alveolar bone loss through the use of anti-sclerostin antibodies) held by THE REGENTS OF THE UNIVERSITY OF MICHIGAN expires Mon May 18 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Grant date
Tue May 23 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 18 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K2039/505, A61K39/3955, A61K45/06, A61P